Literature DB >> 22990302

Renal phosphate handling in Gitelman syndrome--the results of a case-control study.

Cristina Viganò1, Chiara Amoruso, Francesco Barretta, Giuseppe Minnici, Walter Albisetti, Marie-Louise Syrèn, Mario G Bianchetti, Alberto Bettinelli.   

Abstract

BACKGROUND: Patients with Gitelman syndrome, a hereditary salt-wasting tubulopathy, have loss-of-function mutations in the SLC12A3 gene coding for the thiazide-sensitive sodium chloride co-transporter in the distal convoluted tubule. Since the bulk of filtered phosphate is reabsorbed in the proximal tubule, renal phosphate wasting is considered exceptional in Gitelman syndrome.
METHODS: We investigated the renal handling of inorganic phosphate in 12 unselected Italian patients affected with Gitelman syndrome (5 females and 7 males, aged 6.0-18 years, median age 12 years) and in 12 healthy subjects matched for gender and age (controls). The diagnosis of Gitelman syndrome among the patients had been made clinically and confirmed by molecular biology studies.
RESULTS: The biochemical hallmarks of Gitelman syndrome, namely hypochloremia, hypokalemia, hypomagnesemia, increased urinary excretion of sodium, chloride, potassium and magnesium and reduced urinary excretion of calcium, were present in the 12 patients. In addition, both the plasma inorganic phosphate concentration (median and interquartile range: 1.28 [1.12-1.36] vs. 1.61 [1.51-1.66)] mmol/L) and the maximal tubular reabsorption of inorganic phosphate (1.08 [0.99-1.22] vs. 1.41 [1.38-1.47] mmol/L) were significantly lower (P < 0.001) in Gitelman patients than in control subjects. Circulating levels of 25-hydroxyvitamin D, intact parathyroid hormone and osteocalcin were similar in patients and controls.
CONCLUSIONS: The results of our case-control study disclose a hitherto unrecognized tendency towards renal phosphate wasting with mild to moderate hypophosphatemia in Gitelman syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990302     DOI: 10.1007/s00467-012-2297-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

Review 1.  Trends in pubertal development in Europe.

Authors:  S M de Muinich Keizer; D Mul
Journal:  Hum Reprod Update       Date:  2001 May-Jun       Impact factor: 15.610

2.  Hypophosphataemia in a patient with Gitelman's syndrome.

Authors:  K Katopodis; M Elisaf; K C Siamopoulos
Journal:  Nephrol Dial Transplant       Date:  1996-10       Impact factor: 5.992

Review 3.  Thiazide diuretics.

Authors:  H Velázquez
Journal:  Ren Physiol       Date:  1987

Review 4.  Threading through the mizmaze of Bartter syndrome.

Authors:  Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2006-05-16       Impact factor: 3.714

5.  Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group.

Authors:  N X von der Weid; B M Erni; C Mamie; H P Wagner; M G Bianchetti
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

Review 6.  Measurement and estimation of GFR in children and adolescents.

Authors:  George J Schwartz; Dana F Work
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

7.  Identification of fifteen novel mutations in the SLC12A3 gene encoding the Na-Cl Co-transporter in Italian patients with Gitelman syndrome.

Authors:  Marie-Louise Syrén; Silvana Tedeschi; Laila Cesareo; Rosa Bellantuono; Giacomo Colussi; Mirella Procaccio; Anna Alì; Raffaele Domenici; Fabio Malberti; Monica Sprocati; Michele Sacco; Nunzia Miglietti; Alberto Edefonti; Fabio Sereni; Giorgio Casari; Domenico A Coviello; Alberto Bettinelli
Journal:  Hum Mutat       Date:  2002-07       Impact factor: 4.878

8.  Renal tubular function in children and adolescents with Gitelman's syndrome, the hypocalciuric variant of Bartter's syndrome.

Authors:  N Peters; A Bettinelli; I Spicher; E Basilico; M G Metta; M G Bianchetti
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

Review 9.  Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Authors:  Hannsjörg W Seyberth; Karl P Schlingmann
Journal:  Pediatr Nephrol       Date:  2011-04-19       Impact factor: 3.714

Review 10.  FGF-23 in bone biology.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2009-12-15       Impact factor: 3.714

View more
  6 in total

1.  Phosphate homeostasis in Bartter syndrome: a case-control study.

Authors:  Alberto Bettinelli; Cristina Viganò; Maria Cristina Provero; Francesco Barretta; Alessandra Albisetti; Silvana Tedeschi; Barbara Scicchitano; Mario G Bianchetti
Journal:  Pediatr Nephrol       Date:  2014-06-06       Impact factor: 3.714

Review 2.  Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities.

Authors:  T D Filippatos; C V Rizos; E Tzavella; M S Elisaf
Journal:  Int Urol Nephrol       Date:  2017-07-25       Impact factor: 2.370

3.  Persistent mild hypokalemia in an otherwise healthy 6-year-old girl: Answers.

Authors:  Sofia Roumeliotou; Anastasia Theohari; Donatos Tsamoulis; Kyriaki Vafeidou; Iliana Siountri; Ekaterini Siomou
Journal:  Pediatr Nephrol       Date:  2022-02-03       Impact factor: 3.651

4.  Fanconi syndrome and severe polyuria: an uncommon clinicobiological presentation of a Gitelman syndrome.

Authors:  Karim Bouchireb; Olivia Boyer; Lamisse Mansour-Hendili; Arnaud Garnier; Laurence Heidet; Patrick Niaudet; Remi Salomon; Rosa Vargas Poussou
Journal:  BMC Pediatr       Date:  2014-08-11       Impact factor: 2.125

5.  Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report.

Authors:  Aika Miya; Akinobu Nakamura; Hiraku Kameda; Kandai Nozu; Hideaki Miyoshi; Tatsuya Atsumi
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC).

Authors:  Ganesh Pathare; Manuel Anderegg; Giuseppe Albano; Florian Lang; Daniel G Fuster
Journal:  Sci Rep       Date:  2018-02-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.